Table 1.
Demographic and clinical characteristics of the included patients.
| Variables | N = 466 |
|---|---|
| Demographic variables | |
| Age (year) | 61.3 ± 11.9 |
| Male: Female | 388: 78 |
| BMI (kg/m2) | 24.0 ± 3.5 |
| Smoking | 214 (45.9) |
| Alcohol | 149 (32.0) |
| Diabetes | 118 (25.3) |
| Hypertension | 184 (39.5) |
| Etiology | |
| HBV* | 261 (56.0) |
| HCV* | 40 (8.6) |
| Non-B Non-C | 156 (33.5) |
| Child-Pugh score | 5.2 ± 0.4 |
| MELD score | 8.0 ± 2.0 |
| Laboratory variable | |
| Platelet count (109/L) | 201.9 ± 85.3 |
| Total bilirubin (mg/dL) | 0.8 ± 0.4 |
| Serum albumin (g/dL) | 4.1 ± 0.5 |
| Alanine aminotransferase (IU/L) | 48.1 ± 55.7 |
| Prothrombin time (INR) | 1.1 ± 0.1 |
| Creatinine (mg/dL) | 1.0 ± 0.8 |
| Sodium (mmol/L) | 139.6 ± 3.2 |
| Alpha-fetoprotein (ng/mL) | 34.6 (0.4-200000.0) |
| PIVKA-II (mAU/mL) | 936.0 (5.0- 95926.0) |
| Tumor variable | |
| Maximum tumor diameter (cm) | 8.0 ± 3.0 |
| Treatment variable | |
| Initial treatment | |
| Resection | 246 (52.8) |
| Transarterial therapy | 204 (43.8) |
| Chemotherapy | 8 (1.7) |
| Local ablative therapy | 3 (0.6) |
| Radiation | 3 (0.6) |
| Liver transplantation | 2 (0.4) |
*Four patients had underlying hepatitis B and C coinfections.
BMI, body mass index; HBV, hepatitis B virus; HCV, hepatitis C virus; MELD, Model for End-Stage Liver Disease; PIVKA-II, protein induced by vitamin K absence-II.